 CLEARWATER, Fla.--BUSINESS WIRE--Apyx Medical Corporation NASDAQ:APYX the Company, a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market, today reported preliminary revenue results for the full year and fourth quarter ended December 31, 2020. Preliminary Fourth Quarter 2020 Revenue Summary: Total Q4 revenue in a range of approximately 10.9 to 11. 